Final design
Scheme
The first plasmid contains the efflux pump for Nickel (rcnA), which will maintain its natural regulation dependent of metal (by RcnR) and additionally, it will contain a promoter regulated by the repressor of lambda phage, cI. Besides, of course, a resistance as a marker of the plasmid.
The second contains everything needed for regulating the power down from an external signal (AHL). Both luxR as aiiA will occur constitutively, the first one, with a strong promoter (pTetR), as we do not want the presence of LuxR to be limiting, and the second one, having a moderate promoter or weak (pLacZ), to give us space to play with concentrations of AHL without aiiA always wining. And cI *, cI modified with a queue of LVA for rapid degradation, regulated by a promoter dependent of LuxR + AHL. It will also contain an equal resistance as a marker.
In the presence of AHL, this joins with LuxR and induces the production of cI *, which in turn represses the transcription of rcnA. Like cI *, signal AHL has to be short-lived since aiiA is degradating constantly, so the system quickly returns to its initial state once it ceases to manage AHL.
Parts
Defining bioparts we will use or where to get what is necessary.
Part: BBa_I729006
======================================================================
Part of Quorum sensing used by the team Chiba in iGEM2007. Both tetR and LacI + pL are constitutive promoters, but since LacI + pL is a very strong promoter, it will probably be replaced. This biopart will be responsible for the regulation by luxR and the action of the system by AHL. Instead of GFP (Subpart E0040), the BBa_C0051 part that codes for the protein cI + LVA will be inserted, which will join the regulatory region of cI (biopart BBa_R0051) in the other plasmid.
(Previous experience: none)
Part:BBa_C0051
======================================================================
Region coding for the repressor cI based on the repressor cI of lambda phage with modified LVA with a queue for rapid degradation. cI joins the regulator cI (BBa_R0051)
(Previous experience: none)
Part:BBa_R0051
======================================================================
Promoter regulated by cI based on the pR promoter of lambda phage. The promoter has two binding sites to cI repressor of lambda phage (BBa_C0051). The union of cI results in the suppression of the transcript.
(Previous experience: it works)
Of the previous 3 bioparts, the sequence is in the registration of biological parts and according to this page, DNA is available.
Part: BBa_G00510
This is the forward primer of C0051 that has 24 pb.
(No DNA in the bank, but we know that it works)
gatttctgcatagccagacttggg
Part: BBa_G00511
Reverse primer for C0051 that has 26 pb.
cactgactagcgataactttccccac
(No DNA in the bank but we know that it works)
Vectors
We need to define the vectors we can use.
Possibilities:
*The ones recorded in the spreadsheet (courses).
In bioparts:
Name |
Description |
pSB3C5 |
Low to medium copy BioBrick standard vector |
pSB3T5 |
Low to medium copy BioBrick standard vector |
pSB4A3 |
pSB4A3 |
pSB4C5 |
Low copy BioBrick standard vector |
pSB4A1 |
pSB4A1 |
pSB4A5 |
Low copy BioBrick standard vector |
pSB4T5 |
Low copy BioBrick standard vector |
BBa_I739202 |
pCK01BB1 |
Primers
Build or find oligos that we could use for our constructions.
We need:
• rcnA (with its regulatory region; no promoter).
• cI *.
• Constitutive promoter for luxR (tetR is proposed, it is a strong promoter).
• Constitutive promoter for aiiA (lacZ is proposed, it is a moderate promoter).
• aiiA.
• Promoter dependent of cI.
~ In all cases, we have to check whether they already exist (in biopartes or something) and evaluate them.
|
|
Sequence |
Tm |
Deg. |
Restr. S |
Bioparts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
None |
|
|
|
|
|
|
|
|
|
5' GCACCCAGGCTTTACACTTT 3'
|
|
|
None |
|
|
5' TGTTATCCGCTCACAATTCCA 3'
|
|
|
|
|
|
|
5' GATTTCTGCATAGCCAGACTTGGG 3'
|
|
|
None |
|
|
5' CACTGACTAGCGATAACTTTCCCCAC 3'
|
|
|
None |
|
|
|
5' CACTATTAATCTACTGGGGGGTAG3'
|
|
|
None |
|
|
5' AGTTATCGCATTATGCCCATG 3'
|
|
|
None |
|
Promoters
Investigate a little more about the proposed promoters and define whether they are the most optimal.
Promoter |
Biopart |
Constitutive? |
Strength |
Notes |
pTetR |
BBa_R0040 |
In tetracycline presence or TetR absence |
medium |
Recomended by our advisor Miguel |
pLuxR-HSL |
BBa_R0062 |
Over-regulated by LuxR-HSL (increases its expression). |
weak (constitutive)/medium (LuxR-HSL) |
luxR could bring some trouble if it becomes a part of the sistem |
pLacIQ |
BBA_I14032 |
Yes |
high |
¿Is there a biopart? It could be the promoter for luxR |
pCyc |
BBa_I766555 |
Yes |
medium |
Yeast promoter |
J23112 |
BBa_J23113 |
Yes |
1 |
|
J23103 |
BBa_J23113 |
Yes |
17 |
|
J23113 |
BBa_J23113 |
Yes |
21 |
|
J23109 |
BBa_J23113 |
Yes |
106 |
|
J23117 |
BBa_J23113 |
Yes |
162 |
|
J23114 |
BBa_J23113 |
Yes |
256 |
|
J23115 |
BBa_J23113 |
Yes |
387 |
|
J23116 |
BBa_J23113 |
Yes |
396 |
Constitutive promoters family |
J23105 |
BBa_J23113 |
Yes |
62 |
J23110 |
BBa_J23113 |
Yes |
844 |
|
J23107 |
BBa_J23113 |
Yes |
908 |
|
J23106 |
BBa_J23113 |
Yes |
1185 |
|
J23108 |
BBa_J23113 |
Yes |
1303 |
|
J23118 |
BBa_J23113 |
Yes |
1429 |
|
J23111 |
BBa_J23113 |
Yes |
1487 |
|
J23101 |
BBa_J23113 |
Yes |
1791 |
|
J23104 |
BBa_J23113 |
Yes |
1831 |
|
J23102 |
BBa_J23113 |
Yes |
2179 |
|
J23100 |
BBa_J23113 |
Yes |
2547 |
|
Facts about kinetics & other things...
Investigate a little more about the parties involved in the system to begin with an outline of modeling and defining how the design is theoretically feasible.
Note: To join HSLwith LuxR and enable the transcription of cI, HLS should be at a concentration of micromolar order.
Note (2): Not all bioparts have been used previously, most DNA is available but still there is no record of it working. We need to check the quality of DNA to ensure that there will be no problems.
|